胸腺癌帕博利珠单抗治疗反应的分子预测因子。
Molecular predictors of response to pembrolizumab in thymic carcinoma.
机构信息
Meyer Cancer Center, Weill Cornel Medicine, New York, NY 10065, USA.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA.
出版信息
Cell Rep Med. 2021 Sep 3;2(9):100392. doi: 10.1016/j.xcrm.2021.100392. eCollection 2021 Sep 21.
Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here, we characterize the genomic and transcriptomic profile of thymic carcinoma samples from 10 patients (5 non-responders versus 5 responders) in this cohort, with the main aim of identifying potential predictors of response to immunotherapy. We find that expression of and alterations in genes or pathways that correlated with PD-L1 expression ( and ) could be potential predictors for response or resistance to immunotherapy in patients with advanced thymic carcinoma. Our study provides insights into potential predictive markers/pathways to select patients with thymic carcinoma for anti-PD-1 immunotherapy.
胸腺癌较为罕见，其预后较胸腺瘤差。铂类化疗失败后，治疗选择有限。我们之前对晚期胸腺癌患者进行了派姆单抗的单中心二期研究，结果显示缓解率为 22.5%。在这里，我们对该队列中 10 名患者（5 名无应答者与 5 名应答者）的胸腺癌样本进行了基因组和转录组分析，主要目的是确定免疫治疗反应的潜在预测因子。我们发现，表达和与 PD-L1 表达相关的基因或通路的改变（和）可能是晚期胸腺癌患者对免疫治疗有反应或耐药的潜在预测因子。我们的研究为选择胸腺癌患者进行抗 PD-1 免疫治疗提供了潜在的预测标志物/通路的见解。
Zotero 插件